Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.58 USD
-0.05 (-3.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.58 USD
-0.05 (-3.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
by Zacks Equity Research
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
by Zacks Equity Research
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
by Zacks Equity Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.
Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.
Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of 80.00% and 880.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.